Sugi Predict

Sugi Predict / Compounds / SCHEMBL1765241

SCHEMBL1765241

SCHEMBL1765241

Cc1cc(OC(CC(C)(C)C)c2ccc(C(=O)NCC(O)C(=O)O)cc2)cc(C)c1-c1ccc(C(C)(C)C)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GCGR P47871 15/20 0.60
▸ GIPR P48546 2/20 0.41
▸ ADCY6 O43306 1/20 0.39
▸ ADCY3 O60266 1/20 0.39
▸ ADCY9 O60503 1/20 0.39
▸ ADCY5 O95622 1/20 0.39
▸ ADCY8 P40145 1/20 0.39
▸ ADCY7 P51828 1/20 0.39
▸ ADCY2 Q08462 1/20 0.39
▸ ADCY1 Q08828 1/20 0.39
▸ ADCY4 Q8NFM4 1/20 0.39
▸ EPHX2 P34913 2/20 0.38
▸ CHRM5 P08912 1/20 0.38
▸ GLP1R P43220 1/20 0.38
▸ NR1H4 Q96RI1 3/20 0.37
▸ NPC1 O15118 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ CASP3 P42574 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ SENP7 Q9BQF6 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12595490 1.00 GCGR (0.60) GCGRGIPRADCY6ADCY3ADCY9
SCHEMBL12595489 1.00 GCGR (0.60) GCGRGIPRADCY6ADCY3ADCY9
SCHEMBL12595567 0.93 GCGR (0.56) GCGRGIPRCHRM5GLP1R
SCHEMBL1765219 0.93 GCGR (0.56) GCGRGIPRCHRM5GLP1R
SCHEMBL2667233 0.93 GCGR (0.56) GCGRGIPRCHRM5GLP1R
SCHEMBL12595569 0.93 GCGR (0.51) GCGRGIPRCHRM5GLP1RNPC1
SCHEMBL1765371 0.93 GCGR (0.51) GCGRGIPRCHRM5GLP1RNPC1
SCHEMBL1765422 0.92 GCGR (0.57) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL1765372 0.91 GCGR (0.56) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL1765389 0.86 GCGR (0.79) GCGRADCY6ADCY3ADCY9ADCY5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8609892-B2 Glucagon receptor antagonists, preparation and therapeutic uses ELI LILLY AND COMPANY (US) 2013-12-17 — — US claimed
US-20110124648-A1 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2011-05-26 — — US claimed
EP-2159221-A1 Glucagon receptor antagonists, preparation and therapeutic uses Eli Lilly & Company (US) 2010-03-03 — — EP claimed
EP-1758853-B1 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES LILLY CO ELI (US) 2010-01-20 — — EP claimed
US-20070249688-A1 Glucagon Receptor Antagonists, Preparation and Therapeutic Uses ELI LILLY AND COMPANY (US) 2007-10-25 — — US claimed
EP-1758853-A1 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2007-03-07 — — EP claimed
WO-2005123668-A1 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2005-12-29 — — WO claimed
US-20170143673-A1 Methods For Treating Heart Failure Using Glucagon Receptor Antagonists REMD Biotherapeutics, Inc 2017-05-25 — — US disclosed
US-8609892-B2 Glucagon receptor antagonists, preparation and therapeutic uses ELI LILLY AND COMPANY (US) 2013-12-17 — — US disclosed
US-20110124648-A1 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2011-05-26 — — US disclosed
US-20100324140-A1 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2010-12-23 — — US disclosed
US-7816557-B2 3-{4-[1-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]-benzoylamino}-propionic acid; treat diabetic and other glucagon related metabolic disorders ELI LILLY AND COMPANY (US) 2010-10-19 — — US disclosed
EP-2159221-A1 Glucagon receptor antagonists, preparation and therapeutic uses Eli Lilly & Company (US) 2010-03-03 — — EP disclosed
EP-1758853-B1 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES LILLY CO ELI (US) 2010-01-20 — — EP disclosed
US-20070249688-A1 Glucagon Receptor Antagonists, Preparation and Therapeutic Uses ELI LILLY AND COMPANY (US) 2007-10-25 — — US disclosed
EP-1758853-A1 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2007-03-07 — — EP disclosed
WO-2005123668-A1 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2005-12-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124648-A1 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES GLP1R, GCGR, GIPR GCGR 2/4885GIPR 3/4885ADCY6 214/4885
US-20070249688-A1 Glucagon Receptor Antagonists, Preparation and Therapeutic Uses GLP1R, GCGR, GIPR GCGR 2/4885GIPR 3/4885ADCY6 214/4885
US-20170143673-A1 Methods For Treating Heart Failure Using Glucagon Receptor Antagonists GLP1R, GCGR, GIPR GCGR 2/4885GIPR 3/4885ADCY6 555/4885
US-20100324140-A1 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES GLP1R, GCGR, GIPR GCGR 2/4885GIPR 3/4885ADCY6 214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.